Objective To analyze the clinical efficacy of vonoprazan in the treatment of gastroesophageal reflux.Methods 80 patients with gastroesophageal reflux were selected as study subjects.According to the concept of random clinical grouping,all the selected subjects were divided into the conventional group and the combined group,each with 40 cases.The conventional group was treated with rabeprazole sodium enteric-coated tablets in addition to the routine medication regimen,and the combined group was treated with vonoprazan fumarate tablets on the basis of the conventional group.Patients in both groups were compared in terms of clinical efficacy,gastrointestinal hormone levels[pepsinogen Ⅰ(PGⅠ),gastrin-17(G-17)],gastrointestinal mucosal barrier function indexes(diamine oxidase,D-lactic acid),quality of life,occurrence of adverse drug reactions,and disease recurrence.Results The total effective rate of the conventional group was 85.0%(cured in 16 cases,effective in 18 cases,ineffective in 6 cases),and the total effective rate of the combined group was 97.5%(cured in 19 cases,effective in 20 cases,ineffective in 1 case).The total clinical effective rate of the combined group was higher than that of the conventional group(P<0.05).After treatment,the combined group had PGI of(106.75±0.15)ng/ml and G-17 of(53.47±0.13)pmol/L,which were significantly lower than(115.37±0.23)ng/ml and(67.29±0.16)pmol/L in the conventional group(P<0.05).After treatment,the combined group had diamine oxidase of(2.81±0.09)ng/ml and D-lactic acid of(1.85±0.15)mmol/L,which were lower than(3.38±0.12)ng/ml and(2.07±0.38)mmol/L in the conventional group(P<0.05).After treatment,the quality of life score of(84.69±0.26)points in the combined group was higher than(78.46±0.37)points in the conventional group(P<0.05).The incidence of adverse drug reactions was 2.50%in the combined group,which was lower than 15.00%in the conventional group(P<0.05).2 months after the end of treatment,there were 2 cases of recurrence in the conventional group and no recurrence in the combined group,and the recurrence rate in the combined group was slightly lower than that in the conventional group,but there was no significant difference(P>0.05).4 months after the treatment,there were 4 cases of recurrence in the conventional group and 1 case in the combined group,and the recurrence rate in the combined group was slightly lower than that in the conventional group,but there was no significant difference(P>0.05).Conclusion The application of vonoprazan for patients with gastroesophageal reflux can significantly improve their gastrointestinal function,accelerate the recovery of prognosis,enhance the safety of clinical medication,and can be further promoted in clinical practice.
VonoprazanGastroesophageal refluxGastrointestinal function
NETL
NSTL
万方数据
